Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
about
Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders.Immune deficiency and autoimmunity in patients with CTLA-4 (CD152) mutations.Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.Bacille Calmette–Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010–2017.
P2860
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
description
im März 2017 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 28 November 2016
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2017
@uk
name
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@en
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@nl
type
label
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@en
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@nl
prefLabel
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@en
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@nl
P2093
P50
P1476
Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis
@en
P2093
Alexander A Navarini
Annaise Jauch
Anne Kistner
Anne-Valérie Burgener
Annemarie Gabrysch
Barbara-Christina Padberg Sgier
Benedikt Meyer
Bodo Grimbacher
Charlotte Schwab
Christoph Hess
P304
1043-1046.e5
P356
10.1016/J.JACI.2016.08.042
P407
P577
2016-11-28T00:00:00Z